Goldman Sachs Group Inc. boosted its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) by 25.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 686,767 shares of the company’s stock after purchasing an additional 139,126 shares during the period. Goldman Sachs Group Inc.’s holdings in Ginkgo Bioworks were worth $3,915,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Acadian Asset Management LLC acquired a new stake in Ginkgo Bioworks in the first quarter valued at $120,000. Millennium Management LLC increased its holdings in Ginkgo Bioworks by 113.1% in the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock valued at $8,137,000 after purchasing an additional 757,535 shares during the period. AQR Capital Management LLC increased its holdings in Ginkgo Bioworks by 322.6% in the first quarter. AQR Capital Management LLC now owns 158,939 shares of the company’s stock valued at $906,000 after purchasing an additional 121,326 shares during the period. PDT Partners LLC grew its holdings in Ginkgo Bioworks by 104.0% during the 1st quarter. PDT Partners LLC now owns 385,153 shares of the company’s stock worth $2,195,000 after acquiring an additional 196,350 shares during the period. Finally, Cubist Systematic Strategies LLC grew its holdings in Ginkgo Bioworks by 188.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 439,259 shares of the company’s stock worth $2,504,000 after acquiring an additional 287,221 shares during the period. 78.63% of the stock is currently owned by institutional investors and hedge funds.
Get Ginkgo Bioworks alerts:
Ginkgo Bioworks Price Performance
Shares of NYSE:DNA opened at $11.04 on Thursday. The firm has a fifty day moving average price of $11.97 and a two-hundred day moving average price of $9.30. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.00 and a one year high of $16.85. The company has a market cap of $653.57 million, a price-to-earnings ratio of -1.88 and a beta of 1.50.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.44) by $0.34. Ginkgo Bioworks had a negative net margin of 136.56% and a negative return on equity of 43.25%. The company had revenue of $49.60 million during the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. Equities research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. BTIG Research increased their price target on Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a “sell” rating in a report on Monday, August 25th. Cowen reissued a “buy” rating on shares of Ginkgo Bioworks in a research report on Friday, August 8th. Finally, Wall Street Zen raised shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research report on Saturday, August 30th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.50.
Get Our Latest Analysis on Ginkgo Bioworks
Ginkgo Bioworks Company Profile
(Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
Five stocks we like better than Ginkgo Bioworks
Breakout Stocks: What They Are and How to Identify Them
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
Powering Up: A Buy Rating Signals GE Vernova’s AI Tailwinds
Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
The Side of Rate Cuts Nobody Is Telling You About
Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report).
